Stimulant Use Disorder: Methamphetamine, Cocaine, and Treatment

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

What Is Stimulant Use Disorder?

Stimulant use disorder is a clinically recognized pattern of cocaine or amphetamine-type stimulant use in which impaired control, craving, continued use despite harm, and disruption of important activities become persistent concerns. Methamphetamine and cocaine differ in their pharmacology, duration of action, patterns of exposure, and some clinical complications, yet the same core diagnostic and treatment principles apply. Clinicians establish the disorder through an assessment of behavior and impairment over time, rather than through a single toxicology result or an assumption based on how often a person uses a drug. The central treatment priorities are safety, a therapeutic relationship that supports continuing care, evidence-based behavioral interventions, management of co-occurring conditions, and sustained recovery support. ASAM and AAAP clinical guideline.

Stimulant use refers to exposure to a substance that increases central nervous system activity; it includes prescribed use under medical supervision, nonmedical use, and illicit use. Risky stimulant use describes exposure associated with increased likelihood of harm, while stimulant use disorder refers to a diagnosis meeting established clinical criteria. The term substance misuse appears in educational and administrative materials but has inconsistent boundaries; clinical assessment should identify the substance, context, actual harms, and diagnostic features precisely. Addiction describes the broader syndrome of compulsive use and continued engagement despite harm. Physical dependence, tolerance, and withdrawal are related physiological phenomena and alone do not establish addiction. ASAM and AAAP clinical guideline.

For a reader concerned about personal stimulant use, the most useful clinical question is whether stimulant exposure has begun to interfere with control, relationships, health, responsibilities, or the ability to live according to one's intentions. A person can experience serious toxicity without having a substance use disorder; conversely, a person may meet diagnostic criteria even when acute intoxication is absent during an appointment. Evaluation remains worthwhile at either point. The effects of cocaine and methamphetamine can be acute, cumulative, or associated with the broader circumstances of use, which is why treatment must address more than a laboratory finding. ASAM and AAAP clinical guideline.

Cocaine, Methamphetamine, and Other Amphetamine-Type Stimulants

Shared effects and clinically important differences

Cocaine primarily increases extracellular monoamine signaling by inhibiting transporters that normally clear dopamine, norepinephrine, and serotonin. Methamphetamine promotes monoamine release and alters transporter function, producing particularly prominent dopamine and norepinephrine effects. Both can increase wakefulness, energy, arousal, confidence, and reward learning, while also elevating cardiovascular strain and susceptibility to agitation, anxiety, sleep disruption, and psychotic symptoms. The experienced effects vary with exposure, individual vulnerability, co-used substances, and the conditions in which use occurs. ASAM and AAAP clinical guideline.

Cocaine's effect is often relatively brief, and repeated exposure may occur within a short period. Methamphetamine generally has longer-lasting stimulant effects, so prolonged wakefulness and extended periods of intoxication can become especially important to assessment. These distinctions affect symptom timing, sleep recovery, medical observation, and treatment planning. They do not justify ranking individual patients by assumed severity: the degree of clinical harm depends on patterns of use, comorbidity, supply variability, and access to care. ASAM and AAAP clinical guideline.

Prescription stimulants used appropriately for attention-deficit/hyperactivity disorder or other recognized conditions require a separate assessment from the nonmedical use of cocaine or methamphetamine. Therapeutic use under medical supervision does not itself indicate stimulant use disorder, and abrupt changes in prescribed treatment can create other clinical problems. A diagnosis considers impaired control, functional consequences, and the context of medically supervised treatment. ASAM and AAAP clinical guideline.

Routes of exposure, drug supply, and combined substances

The way a stimulant enters the body changes the speed of effect, potential injury, and opportunities for infectious disease exposure. Smoking and injection can intensify rapid delivery and carry distinct respiratory, vascular, or infectious complications. Snorting cocaine may injure nasal tissues, and ingestion introduces another pattern of onset. Clinicians ask about these exposures to tailor medical assessment and harm reduction without treating the route alone as a diagnosis or moral classification. ASAM and AAAP clinical guideline.

Unregulated drug supplies can contain unexpected substances. In particular, fentanyl or other opioids may be present alongside stimulants, and intentional stimulant-opioid co-use also occurs. This changes overdose risk because opioid-related respiratory depression can occur in someone who expected a stimulant effect. Alcohol, benzodiazepines, opioids, and other drugs can complicate intoxication and withdrawal; cocaine taken with alcohol can form cocaethylene, a pharmacologically active metabolite relevant to cardiac risk. Accurate assessment therefore considers all reported and possible exposures. ASAM and AAAP clinical guideline.

Symptoms and Diagnostic Criteria

Impaired control and consequences across daily life

DSM-5-TR substance use disorder criteria, applied to the stimulant class, cover impaired control over amount and duration of use; unsuccessful efforts to cut down; time devoted to obtaining, using, or recovering from stimulants; craving; failures in major responsibilities; social and interpersonal consequences; activities reduced or abandoned; use in hazardous situations; continued use despite known physical or psychological problems; and certain physiological adaptations. A qualifying pattern generally involves at least two relevant criteria within a twelve-month period and clinically significant impairment or distress. Mild, moderate, and severe classifications reflect the number of qualifying criteria, not a biochemical measurement or a patient's social worth. ASAM and AAAP clinical guideline.

Tolerance means that a familiar effect requires greater exposure, or the same exposure produces a diminished effect. Withdrawal refers to a characteristic syndrome after reduction or cessation following repeated exposure. These may be relevant clinical findings, but their meaning depends on context. Physiological adaptations associated with appropriate prescribed stimulant treatment must be interpreted according to diagnostic rules for use under medical supervision. Clinical records should distinguish signs of adaptation from compulsive nonmedical use, particularly when a patient also has ADHD or a sleep disorder. ASAM and AAAP clinical guideline.

Craving can be experienced as a recurring urge associated with people, places, emotions, memories, fatigue, or drug cues. Repeated use may continue despite financial strain, difficulty maintaining employment, sleep deprivation, conflict, or medical symptoms. These patterns are clinically meaningful when they reflect sustained impairment and loss of control. Many individuals experience both stimulant use disorder and other substance use disorders, requiring more than one diagnostic formulation. ASAM and AAAP clinical guideline.

Diagnosis, screening, and toxicology

Screening identifies a reason to investigate. A brief questionnaire or a positive test cannot establish the full diagnosis. Comprehensive assessment includes a longitudinal history of use and attempted change, functional impairment, psychiatric symptoms, medical history, medications, other substances, and the individual's immediate goals. It also establishes acute safety needs, including chest pain, respiratory problems, neurological symptoms, marked agitation, confusion, psychosis, suicidal thoughts, and exposure to potentially dangerous combinations. ASAM and AAAP clinical guideline.

Urine or other toxicology testing can provide useful supplementary information about recent exposure but has detection-window, sensitivity, specificity, and interpretive limitations. Immunoassays can produce false-positive or false-negative findings and often require confirmatory methods when a result will change important care decisions. A negative test does not rule out a disorder, and a positive test does not measure the number of diagnostic criteria. Collaborative interpretation is preferable to punitive use of testing, which can weaken disclosure and retention. ASAM and AAAP clinical guideline.

A meaningful differential assessment considers ADHD, bipolar disorder, primary psychotic disorders, anxiety disorders, trauma-related symptoms, medication effects, sleep deprivation, and other medical or neurological causes. Substance-induced symptoms may resemble independent conditions, and their timing relative to exposure, prior history, persistence, and recurrence helps clinicians evaluate the relationship. The clinical classification of psychosis warrants its own examination, while stimulant treatment requires a practical safety assessment whenever hallucinations, delusions, or disorganization are present. ASAM and AAAP clinical guideline.

Why Stimulant Use Can Become Compulsive

Reward learning, cues, and incentives

Stimulants alter signaling within neural systems involved in reward prediction, salience, motivation, attention, stress responsiveness, and action selection. Dopamine contributes to learning about rewards and cues, but neither a single neurotransmitter nor a single brain region explains the full disorder. Repeated exposure may strengthen associations between a substance and particular settings, states of mind, or routines. Those learned associations can generate powerful urges even when the person understands the negative consequences of use. ASAM and AAAP clinical guideline.

Positive reinforcement refers to behavior strengthened by rewarding or desired experiences such as euphoria, energy, connection, or enhanced perceived performance. Negative reinforcement refers to behavior strengthened when it relieves unpleasant states, including low mood, fatigue, or distress. Across time, the relative contribution of these processes can shift. This helps explain why a person may continue using despite progressively less pleasure, while fatigue, cues, and emotional pain maintain urges. The model is clinically useful when integrated with social learning, health, opportunity, and environmental conditions. ASAM and AAAP clinical guideline.

Genetics, stress, development, and environment

Vulnerability to stimulant use disorder reflects multiple interacting determinants. Family and genetic influences, adolescent exposure, trauma histories, co-occurring psychiatric symptoms, chronic stress, drug availability, social isolation, poverty, and unstable housing may each affect risk or recovery. Observational associations require careful interpretation: an association between adversity and stimulant use does not prove a simple, one-way causal path. People differ in protective relationships, community resources, health, and capacity to seek care. ASAM and AAAP clinical guideline.

A biopsychosocial formulation links the patient's motives for use, current health, daily circumstances, and sustaining reinforcers. It asks what the stimulant is doing within a life: managing exhaustion, prolonging work, altering social experience, temporarily shifting mood, responding to trauma reminders, or producing anticipated pleasure. These functions are hypotheses to assess collaboratively, not reasons to assume that everyone shares the same cause. Treatment becomes more precise when it addresses the real functions of use while strengthening available alternatives. ASAM and AAAP clinical guideline.

Acute Intoxication and Medical Emergencies

Recognizing stimulant toxicity

Acute stimulant intoxication may produce elevated heart rate and blood pressure, sweating, dilated pupils, agitation, restlessness, anxiety, insomnia, tremor, or suspiciousness. More severe presentations can include hyperthermia, arrhythmia, cardiac ischemia, stroke, seizures, severe confusion, delirium, or psychosis. Toxicity can occur independently of a chronic stimulant use disorder. Clinicians determine urgency from vital signs, mental status, symptoms, possible substances, and the progression of the presentation. ASAM and AAAP clinical guideline.

Chest pain; a seizure; marked overheating; collapse; severe shortness of breath; new weakness or speech difficulty; dangerous agitation or confusion; or signs of stroke warrant immediate emergency medical evaluation. Suspected opioid contamination adds a different urgent pattern: unresponsiveness and slow, irregular, or absent breathing require emergency services and naloxone when available. Naloxone reverses opioid effects and does not directly treat stimulant toxicity, so emergency evaluation remains essential even after its use. ASAM and AAAP clinical guideline.

Clinical management of severe intoxication centers on rapid evaluation, a safe environment, physiological monitoring, investigation of cardiac and neurological complications, and symptom-directed medical treatment. Agitation and severe sympathomimetic effects may require professionally administered medication and repeated reassessment. Patients with severe toxicity belong in appropriately equipped emergency or inpatient settings. The scientific principles of acute management must not be translated into home-treatment dosing or unsupervised sedation. ASAM and AAAP clinical guideline.

Psychosis, suicidal thoughts, and other psychiatric emergencies

Hallucinations, fixed false beliefs, paranoia, and severe disorganization may occur during or following stimulant exposure. Sleep deprivation, co-used substances, and previous psychiatric vulnerability can contribute. The immediate clinical task is safety, identification of reversible medical contributors, and assessment of whether symptoms require emergency psychiatric or medical care. Longitudinal follow-up helps distinguish transient substance-associated symptoms from an independent psychotic disorder, a question requiring a dedicated differential diagnostic evaluation. ASAM and AAAP clinical guideline.

Stimulant intoxication, the period when its effects fade, and the early withdrawal period can be associated with acute emotional instability and increased suicide risk. Suicidal intent, inability to remain safe, severe psychosis, or violent agitation calls for immediate professional evaluation. Clinicians should also ask about depression, trauma, self-harm, and access to lethal means as relevant to the patient. After stabilization, continuity of care is essential because an emergency visit alone does not address persistent stimulant use disorder. ASAM and AAAP clinical guideline.

Stimulant Withdrawal and the Early Recovery Period

When repeated stimulant exposure stops or falls sharply, people may experience fatigue, a need for prolonged sleep or disrupted sleep, increased appetite, psychomotor slowing or agitation, reduced pleasure, irritability, anxiety, and depressive symptoms. Craving and cue sensitivity may persist beyond the most intense early symptoms. Experiences and timelines vary substantially, especially when cocaine, methamphetamine, other substances, sleep deprivation, and psychiatric illness overlap. Clinicians should evaluate physical health, nutrition, sleep, psychiatric risk, and the possibility of simultaneous withdrawal from other drugs. ASAM and AAAP clinical guideline.

Stimulant withdrawal is generally approached differently from the potentially life-threatening withdrawal syndromes associated with alcohol and benzodiazepine dependence. Its clinical seriousness may still be high because severe depression, suicidality, psychosis, exhaustion, or inability to care for oneself can demand supervised care. If a person also has physiological dependence on alcohol, benzodiazepines, or another sedative, medical withdrawal risks must be assessed separately. A universal home detoxification schedule cannot safely address these combinations. ASAM and AAAP clinical guideline.

Withdrawal management is one phase of care. Restoring sleep, food intake, hydration, and safety may help the person participate in treatment, while a longer-term plan addresses craving, reinforcement patterns, mental health, social circumstances, and return-to-use risk. Symptoms that persist, worsen, or appear outside expected temporal relationships require reassessment rather than being attributed automatically to withdrawal. Recovery is measured through sustained health and functioning as well as substance-use outcomes. ASAM and AAAP clinical guideline.

Evidence-Based Treatment: What Works Best?

Contingency management as the core evidence-based approach

Contingency management provides structured, predictable reinforcement for specified treatment-related behaviors, often including objectively verified reductions in stimulant use or engagement with care. Its rationale is grounded in learning theory: immediate, reliable reinforcement can compete with the powerful short-term reinforcement associated with stimulants. Programs differ in their target behaviors, reward schedules, verification methods, duration, and delivery setting. Implementation should preserve transparency, patient dignity, and treatment access. ASAM and AAAP clinical guideline.

The 2024 ASAM/AAAP guideline identifies contingency management as the most effective studied treatment component and recommends it as a primary part of stimulant use disorder care. A large meta-analysis of 157 cocaine-treatment studies and 15,842 participants found that contingency management was the only treatment category consistently associated with a higher likelihood of cocaine-negative testing across its comparisons, with an odds ratio of 2.13 and a 95% confidence interval of 1.62 to 2.80. These are treatment-study outcomes, not a guarantee that an individual will achieve permanent abstinence. ASAM and AAAP clinical guideline; Bentzley and colleagues, 2021.

A 2024 Cochrane review found high-certainty evidence that psychosocial treatments as a group reduce dropout compared with no treatment or usual care in the studied contrasts; results for use reduction depended on the comparator. Because comparisons combine settings and therapeutic approaches, the findings should be interpreted according to outcome and design. This supports the practical value of engaging and retaining people in care, while the relative durability of changes after incentives end remains an important implementation and research question. Minozzi and colleagues, 2024.

Cognitive behavioral therapy, community reinforcement, and the Matrix Model

Cognitive behavioral therapy helps patients recognize patterns among situations, interpretations, emotions, urges, and actions. Clinical work may include coping with craving, anticipating high-risk situations, solving problems, responding to setbacks, and building alternatives to stimulant use. CBT is supported by guideline evidence and may be paired with contingency management. Specific benefits depend on how treatment is delivered, which outcomes are studied, and whether people can remain engaged long enough to use the skills in daily life. ASAM and AAAP clinical guideline.

The community reinforcement approach strengthens rewarding activities and relationships that can compete with substance use, integrating functional analysis, practical problem-solving, and social reinforcement. The Matrix Model combines elements such as structured individual and group work, relapse-prevention education, family involvement, and treatment monitoring; it has often been studied in stimulant treatment programs. The ASAM/AAAP guideline names community reinforcement, CBT, and the Matrix Model among preferred psychosocial options alongside contingency management, while assigning different certainty levels to the underlying evidence. ASAM and AAAP clinical guideline.

Motivational interviewing can support an individual's exploration of ambivalence and commitment to personally meaningful changes. It often serves as an engagement method within broader care. Its role should be characterized according to trial outcomes rather than treated as an equivalent replacement for a well-implemented contingency management program. Trauma-informed practice, accessible scheduling, telehealth options, and a respectful therapeutic relationship influence whether any intervention is usable in real-world settings. ASAM and AAAP clinical guideline.

What treatment studies can and cannot establish

Trials often define improvement using self-report, treatment attendance, retention, biological evidence of abstinence, longest continuous abstinence, or changes in the frequency of use. These outcomes answer related but distinct questions. A higher probability of a stimulant-negative urine test during treatment does not itself establish improved employment, reduced mortality, permanent abstinence, or recovery after treatment ends. Studies also vary in whether participants use cocaine or methamphetamine, receive medication for opioid use disorder, experience homelessness, or have co-occurring psychiatric diagnoses. Such differences limit simple generalization. Minozzi and colleagues, 2024.

In a systematic review and network meta-analysis of 72 randomized trials involving 6,836 participants with amphetamine or methamphetamine use disorders, the certainty of evidence for many treatment contrasts was low or very low and no intervention demonstrated moderate-to-high-certainty benefits across the study's patient-important outcomes. This conclusion depends on the network's heterogeneous comparisons and differs in scope from ASAM's broader clinical recommendations. The two sources should be read together: the clinical guideline supports contingency management as the leading practical intervention, while the review warns against unwarranted precision about comparative effects across every treatment, population, and endpoint. Khalili and colleagues, 2024.

Medications for Stimulant Use Disorder

Clinical status and the meaning of off-label use

Unlike opioid use disorder, for which several medications have established regulatory indications, stimulant use disorder currently lacks an FDA-approved medication specifically indicated to treat the disorder. The ASAM/AAAP guideline nevertheless permits carefully selected off-label pharmacotherapy for some patients and makes conditional recommendations that differ by cocaine versus amphetamine-type stimulant use, comorbidity, and clinical context. The absence of a specific FDA indication should not be confused with the absence of any experimental or potentially useful pharmacological evidence; it means that no medication has an approved indication and a uniformly established benefit for this diagnosis. ASAM and AAAP clinical guideline.

Medication selection requires specialist judgment about cardiovascular risk, psychiatric history, seizure risk, medication interactions, opioid exposure, pregnancy, adherence, and monitoring. Prescribing certain controlled stimulants off-label for stimulant use disorder calls for particular expertise and close follow-up. This article describes evidence status rather than a self-treatment regimen, and it provides no drug doses or instructions for medication substitution. ASAM and AAAP clinical guideline.

Naltrexone plus bupropion for methamphetamine use disorder

The ADAPT-2 randomized trial examined extended-release injectable naltrexone combined with extended-release bupropion among adults with methamphetamine use disorder. Across the trial's sequential stages, the weighted response was 13.6% in the medication condition and 2.5% in the placebo condition, an absolute difference of 11.1 percentage points. The study used a stringent urine-test definition of response and documented adverse events, including serious events. Its findings support a real but limited and population-specific treatment signal, rather than a broadly effective cure. Trivedi and colleagues, 2021.

This combination remains an off-label clinical option, with eligibility, safety screening, and ongoing monitoring determined by the treating clinician. Naltrexone can conflict with ongoing opioid use or opioid-based treatments and requires appropriate assessment. A follow-up analysis suggested additional reductions in methamphetamine use over the studied treatment period but does not resolve long-term effectiveness or generalizability. Evidence for methamphetamine use disorder should not be automatically transferred to cocaine use disorder. Trivedi and colleagues, 2021; Li and colleagues, 2024.

Other medications studied for cocaine and amphetamine-type stimulants

The ASAM/AAAP guideline conditionally discusses bupropion, topiramate, mirtazapine, long-acting psychostimulant formulations, and selected combinations for specified stimulant disorders and patient characteristics. The strength and direction of evidence differ among agents, and some recommendations rely on low-certainty findings. Potential benefit is often linked to a particular population or comorbid disorder rather than an expectation that all people with stimulant use disorder should receive the same medication. ASAM and AAAP clinical guideline.

For cocaine use disorder, a 2021 comparative meta-analysis found evidence favoring contingency management rather than any broad class of medication for the objectively measured cocaine-use outcome analyzed. This does not invalidate all individual medication trials; it demonstrates the need to distinguish single-study or subgroup signals from consistently replicated, patient-relevant effects. Novel medication approaches remain research questions until efficacy, safety, durability, and clinical usefulness are adequately established. Bentzley and colleagues, 2021; ASAM and AAAP clinical guideline.

Personalized Treatment Planning and Continuity of Care

Outpatient care, intensive treatment, and hospitalization

The appropriate level of care follows acute medical and psychiatric safety, the severity and stability of substance-related problems, available support, other drug exposures, and an individual's ability to participate in treatment. Many people can receive care in outpatient settings, often with behavioral programs and coordinated medical services. Severe intoxication, suicidal crises, uncontrolled psychiatric symptoms, serious medical complications, or inability to maintain safety can justify emergency stabilization and more intensive care. The setting itself does not define treatment quality; access to effective interventions and continuity are decisive. ASAM and AAAP clinical guideline.

Programs work better when they can address housing instability, transportation, cost, confidentiality, stigma, and scheduling barriers. Telehealth can extend delivery of evidence-based behavioral care for suitable patients, while digital therapeutic components are best evaluated as adjuncts rather than replacements for comprehensive care. The ASAM/AAAP guideline favors integration of structured behavioral interventions and careful attention to follow-up. Treatment should remain open to people who have not yet reached abstinence, because ongoing engagement can reduce risk and create additional opportunities for change. ASAM and AAAP clinical guideline.

Co-occurring psychiatric and substance use disorders

ADHD, anxiety disorders, depressive disorders, trauma-related disorders, psychotic symptoms, and additional substance use disorders can coexist with stimulant use disorder. Effective planning distinguishes symptoms arising during intoxication or withdrawal from those that precede or continue independently of exposure. Clinical uncertainty may require repeated assessment over time, and acute symptoms still deserve treatment when their cause has not been fully established. Integrated care reduces fragmentation between addiction, primary care, emergency services, and mental health treatment. ASAM and AAAP clinical guideline.

Patients using stimulants alongside opioids require attention to overdose prevention and evidence-based opioid use disorder treatment when indicated. A 2026 systematic review and meta-analysis of 26 trials with 2,356 participants found improved stimulant-opioid negative toxicology outcomes with contingency management in studied co-use populations. Most evidence concerned cocaine and heroin; fentanyl-specific trial evidence was absent, limiting transfer to today's synthetic-opioid supply. The findings support integrated reinforcement-based care while underscoring the need to assess real-world opioid exposure and mortality risks separately. Jegede and colleagues, 2026.

Harm Reduction and Secondary Prevention

Evidence-based care includes practical steps to reduce infectious, cardiovascular, and overdose harms while treatment goals develop. Depending on the person's circumstances, services may include nonjudgmental drug-supply education, access to sterile equipment and infectious disease testing, safer sexual health services, naloxone access, education about suspected opioid contamination, and rapid connections to medical evaluation. Drug checking and fentanyl test strips can provide risk information, but a negative result cannot establish that an illicit supply is safe; sampling and test limitations matter. ASAM and AAAP clinical guideline.

For any suspected overdose, emergency services should be contacted promptly. If an opioid may be involved and the person is unresponsive or breathing abnormally, naloxone is an appropriate emergency intervention where available, alongside emergency-response instructions. Stimulant-related chest pain, seizures, severe hyperthermia, confusion, or stroke symptoms require urgent evaluation even when opioids are not suspected. These are distinct clinical pathways and may overlap in polysubstance emergencies. ASAM and AAAP clinical guideline.

Harm reduction complements treatment because reduced exposure to preventable injury can keep people alive and connected to care. A person-centered plan may track fewer episodes of use, reduced exposure to injection-related harms, safer housing, consistent medical care, or greater control, alongside abstinence outcomes when those are the individual's goals. A care system that only accepts a single endpoint may miss important intermediate clinical gains and discourage return to treatment after setbacks. ASAM and AAAP clinical guideline.

Recovery, Recurrence, and Long-Term Functioning

Recovery refers to a multidimensional process involving health, personal agency, relationships, and functioning over time. Remission refers to a defined diagnostic state in which criteria are no longer met for a specified period, subject to classification rules. A recurrence of use may or may not fulfill criteria for renewed disorder; the colloquial term relapse is used in variable ways and should be clarified in clinical discussion. Regular review of sleep, mood, work, housing, social support, and physical health gives a fuller picture than one test result. ASAM and AAAP clinical guideline.

Stimulant-related cues and fatigue can continue to influence behavior after the acute withdrawal phase. A recovery plan may therefore include repeated access to behavioral treatment, coping and sleep strategies, meaningful daily routines, trusted relationships, supported employment or education, and planned responses to renewed use. A setback is a signal to reassess triggers, treatment fit, and safety needs. Some individuals choose sustained abstinence as their central goal; others initially seek reductions in risk and improvements in function while remaining engaged in care. ASAM and AAAP clinical guideline.

Family and peer support can improve practical access to treatment, accountability, companionship, and hope when these relationships are safe and wanted. They should not be treated as a substitute for medical assessment or evidence-based clinical care. Recovery pathways differ according to age, exposure history, mental health, material resources, and individual priorities. The long-term task is to make healthy behavior increasingly feasible and reinforcing in everyday life. ASAM and AAAP clinical guideline.

Special Populations and Clinical Contexts

Adolescents and emerging adults

Young people require developmentally appropriate screening, attention to confidentiality and consent rules, family and school context, and assessment of co-occurring mental health concerns. Adolescent stimulant use can coexist with other substance exposure, ADHD, trauma, and social stressors. A positive screen invites a careful conversation and further evaluation; it does not determine the diagnosis or justify a one-size-fits-all response. Evidence for some adult pharmacological approaches cannot be assumed to apply to younger patients. ASAM and AAAP clinical guideline.

Pregnancy and postpartum care

Pregnancy changes the clinical stakes of stimulant exposure because both maternal health and pregnancy-related outcomes require attention. Evaluation should address medical and psychiatric complications, prenatal care, co-exposures, nutrition, safety, and access to supportive obstetric and addiction services. Decisions about medication, treatment setting, and monitoring require individualized specialist assessment. Fear of punitive consequences can interfere with honest disclosure and engagement, making respectful and coordinated perinatal care particularly important. ASAM and AAAP clinical guideline.

Older adults, chronic illness, and structural barriers

Older adults and people with cardiovascular disease, neurological disorders, kidney disease, or complex medication regimens may experience different medical risks and require closer review of interactions and functional status. People experiencing homelessness or unstable access to food and transportation may have difficulty participating in frequent treatment visits without practical support. Clinical planning should therefore combine diagnostic accuracy and medical treatment with accommodations that make follow-through realistic. System-level barriers affect observed outcomes and should not be mislabeled as patient unwillingness. ASAM and AAAP clinical guideline.

Digital Treatment, AI Chatbots, and Experimental Approaches

Digital programs can deliver reminders, structured CBT exercises, telehealth visits, recovery check-ins, and contingency management components. They differ in whether they are evidence-based clinical interventions, general wellness applications, unvalidated chatbots, or conversational companions. The ASAM/AAAP guideline supports evidence-based digital behavioral interventions as adjuncts, not standalone treatment for stimulant use disorder. The evidence attached to one validated program cannot be transferred to an unrelated AI companion or general-purpose chatbot. ASAM and AAAP clinical guideline.

AI systems may help with information access or practical organization, but their clinical safety, privacy practices, response to suicidality, and effectiveness require independent testing. Human clinical oversight remains necessary where intoxication, psychosis, complex comorbidity, or medication decisions are involved. Psychedelic-assisted approaches and neuromodulation are subjects of ongoing research; they are not established replacements for contingency management or comprehensive addiction care. Promotional descriptions of innovation cannot substitute for controlled evidence and monitoring of adverse events. ASAM and AAAP clinical guideline.

Interpreting the Strength of the Scientific Evidence

Established clinical practice includes assessment of impaired control and consequences, emergency evaluation of serious intoxication, and contingency management as a leading behavioral intervention supported by guideline recommendations and comparative research. The evidence also supports the importance of sustained engagement, assessment of comorbidity, and matching medical treatment to actual risks. Established does not mean that every outcome or patient population has identical evidence quality; the treatment question and comparator remain essential. ASAM and AAAP clinical guideline; Minozzi and colleagues, 2024.

Preliminary or limited evidence includes many medication strategies, some subgroup-based recommendations, and emerging digital interventions. The ADAPT-2 study provides an informative randomized signal for one combination in one methamphetamine-treatment population, and its modest absolute response rate matters as much as statistical significance. Comparative reviews also show heterogeneity and often low certainty, especially when treatment duration, outcome definitions, and study populations vary. Trivedi and colleagues, 2021; Khalili and colleagues, 2024.

Contested or unresolved questions include how best to sustain outcomes after structured incentives end, which medication combinations benefit which patients, how results apply to fentanyl-era stimulant-opioid co-use, and which long-term patient-defined functional outcomes should carry the greatest weight in trials. These are scientifically important uncertainties rather than reasons to withhold currently supported behavioral treatment. Clinical decisions should be updated as higher-quality trials and guidelines emerge, with the current patient’s safety and preferences remaining central. Jegede and colleagues, 2026; ASAM and AAAP clinical guideline.

Frequently Asked Questions

Is stimulant use disorder the same as using cocaine or methamphetamine?

No. Cocaine or methamphetamine exposure can be hazardous, and a single episode can produce an emergency, but a stimulant use disorder diagnosis requires a qualifying pattern of symptoms and impairment. A clinician evaluates behavior over time, the effects on daily life, and medical and psychiatric context. The distinction supports both early prevention for risky use and appropriate treatment for a recognized disorder. ASAM and AAAP clinical guideline.

What is the most effective treatment for stimulant use disorder?

Contingency management has the strongest overall evidence among studied treatment components and is recommended as a primary element of care by ASAM and AAAP. Cognitive behavioral therapy, community reinforcement, and the Matrix Model are relevant companions depending on patient needs and service availability. Comprehensive treatment also includes screening for acute harm, mental health care, and support for continued engagement. ASAM and AAAP clinical guideline; Bentzley and colleagues, 2021.

Is there an FDA-approved medication for cocaine or methamphetamine use disorder?

No medication is currently FDA-approved specifically for either disorder. Clinicians may consider selected off-label medications after weighing the clinical evidence and patient-specific risks. Research on naltrexone combined with bupropion is relevant to methamphetamine use disorder, while cocaine and amphetamine-type treatment recommendations must be evaluated separately. ASAM and AAAP clinical guideline; Trivedi and colleagues, 2021.

Can someone have withdrawal from stimulants?

Yes. Fatigue, sleep changes, increased appetite, low mood, and craving can occur after sustained exposure is reduced or stopped. The severity and duration vary. Severe depression, suicidal thoughts, psychosis, inability to stay safe, or withdrawal involving alcohol or sedatives requires prompt clinical assessment. ASAM and AAAP clinical guideline.

How does treatment change when stimulants and opioids are both involved?

Clinicians address both disorders and their immediate hazards. Opioid overdose prevention, naloxone access, and evidence-based medication treatment for opioid use disorder may be indicated, while contingency management can target stimulant-related outcomes. Evidence from co-use trials is promising but often reflects cocaine and heroin rather than fentanyl, so clinical decisions must address current supply conditions and individual exposure. Jegede and colleagues, 2026.

What indicates urgent medical care?

Chest pain, stroke-like symptoms, seizures, collapse, dangerous overheating, severe agitation or confusion, psychosis with inability to remain safe, suicidal intent, or abnormal breathing after possible opioid exposure all warrant emergency assistance. Naloxone should be used for suspected opioid overdose when available, according to emergency-response guidance, while the person receives professional medical attention. ASAM and AAAP clinical guideline.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — the broad scientific foundation connecting substance-specific disorders, treatment, harm reduction, and recovery.

Substance-Induced Psychosis: Causes, Symptoms, and Treatment — clinical differentiation and care for psychotic symptoms associated with substance exposure.

Drug-Induced Psychosis vs. Schizophrenia: How Clinicians Tell the Difference — assessment of temporal patterns and independent psychotic illness.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — anxiety mechanisms and cross-diagnostic clinical assessment.

Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care — integration of addiction and psychosis treatment.

Neuroticism and Addiction: Substance Use, Negative Affect, and Risk — personality-linked vulnerability and negative affect as a research bridge.

Cocaine Use Disorder: Symptoms, Cardiovascular Risks, and Treatment — cocaine-specific disorder, acute cardiovascular risks, and evidence-based care.

Methamphetamine Use Disorder: Symptoms, Psychosis Risk, and Care — methamphetamine-related disorder, health harms, psychosis risks, and treatment.

Contingency Management for Substance Use Disorders: Research and Effectiveness — incentive-based behavioral treatment and outcomes for stimulant and other disorders.

References

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. Journal of Addiction Medicine, 18(1), 1–56. https://doi.org/10.1097/ADM.0000000000001299.

Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., and Halpern, C. H. (2021). Comparison of treatments for cocaine use disorder among adults: A systematic review and meta-analysis. JAMA Network Open, 4(5), e218049. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779686.

Jegede, O. O., Oliva, H. N. P., Prudente, T. P., Rash, C. J., Muvvala, S. B., and Angarita, G. A. (2026). Contingency management for stimulant-opioid co-use: A systematic review and meta-analysis. Journal of Addiction Medicine. https://doi.org/10.1097/ADM.0000000000001708.

Khalili, M., Sadeghirad, B., Bach, P., Crabtree, A., Javadi, S., Sadeghi, E., et al. (2024; journal issue 2025). Management of amphetamine and methamphetamine use disorders: A systematic review and network meta-analysis of randomized trials. International Journal of Mental Health and Addiction, 23, 4768–4786. https://doi.org/10.1007/s11469-024-01379-w.

Li, M. J., Chau, B., Belin, T., Carmody, T., Jha, M. K., Marino, E. N., et al. (2024). Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial. Addiction, 119, 1840–1845. https://doi.org/10.1111/add.16529.

Minozzi, S., Saulle, R., Amato, L., Traccis, F., and Agabio, R. (2024). Psychosocial interventions for stimulant use disorder. Cochrane Database of Systematic Reviews, CD011866. https://doi.org/10.1002/14651858.CD011866.pub3.

Trivedi, M. H., Walker, R., Ling, W., Dela Cruz, A., Sharma, G., Carmody, T., et al. (2021). Bupropion and naltrexone in methamphetamine use disorder. New England Journal of Medicine, 384, 140–153. https://doi.org/10.1056/NEJMoa2020214.